The FDA's upcoming advisory committee meeting on Oct. 30 has renewed optimism in the eye care community around SYD-101, Sydnexis's stabilized low-dose atropine 0.01% formulation for slowing pediatric myopia. The drug was denied approval in October 2025 despite meeting its primary phase 3 efficacy endpoint — a decision that frustrated many clinicians who see a clear unmet need for a regulated, stable alternative to compounded atropine.

Pediatric ophthalmologists Drs. M. Edward Wilson and Douglas R. Fredrick argue the FDA's review was overly surface-level. They believe averaging results across age groups masked strong efficacy signals in younger, faster-progressing patients — and that the absence of axial length as a study endpoint further complicated the FDA's assessment. Both experts remain cautiously optimistic that a deeper look at the data could lead to conditional approval, potentially with age-specific labeling.

On genetic testing for myopia, the experts agreed it's not ready for routine use. They support targeted testing for high-risk conditions like Stickler or Marfan syndrome but warn that broad panels in typical myopia cases can generate variants of unknown significance, causing unnecessary family anxiety.

Key Takeaways:

• SYD-101 met its phase 3 primary endpoint but was still denied FDA approval — a rare and contentious outcome
• Subgroup analyses in younger, faster-progressing children may show stronger efficacy that averaged trial data obscured
• Genetic testing for myopia should be reserved for suspected syndromic cases; routine testing is premature and potentially harmful

Why it matters: With childhood myopia rates rising globally, clinicians urgently need a stable, FDA-approved atropine option. The Oct. 30 advisory meeting could be a turning point — not just for SYD-101, but for how the FDA evaluates myopia control therapies going forward.